Literature DB >> 26500059

CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

A-S Tigan1, F Bellutti1, K Kollmann1,2, G Tebb3, V Sexl1.   

Abstract

The G1 cell-cycle kinase CDK6 has long been thought of as a redundant homolog of CDK4. Although the two kinases have very similar roles in cell-cycle progression, it has recently become apparent that they differ in tissue-specific functions and contribute differently to tumor development. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. These functions point to a role of CDK6 in tissue homeostasis and differentiation that is partially independent of CDK6's kinase activity and is not shared with CDK4. We review the literature on the contribution of CDK6 to transcription in an attempt to link the new findings on CDK6's transcriptional activity to cell-cycle progression. Finally, we note that anticancer therapies based on the inhibition of CDK6 kinase activity fail to take into account its kinase-independent role in tumor development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26500059     DOI: 10.1038/onc.2015.407

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  174 in total

Review 1.  FOXM1, a typical proliferation-associated transcription factor.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Biol Chem       Date:  2007-12       Impact factor: 3.915

Review 2.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

3.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

4.  Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.

Authors:  M Chilosi; C Doglioni; Z Yan; M Lestani; F Menestrina; C Sorio; A Benedetti; F Vinante; G Pizzolo; G Inghirami
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

5.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

Review 6.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

7.  Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.

Authors:  Chenguang Wang; Nagarajan Pattabiraman; Jian Nian Zhou; Maofu Fu; Toshiyuki Sakamaki; Chris Albanese; Zhiping Li; Kongming Wu; James Hulit; Peter Neumeister; Phyllis M Novikoff; Michael Brownlee; Philipp E Scherer; Joan G Jones; Kathleen D Whitney; Lawrence A Donehower; Emily L Harris; Thomas Rohan; David C Johns; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

9.  Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.

Authors:  Esther Rodríguez-Díez; Victor Quereda; Florian Bellutti; Michaela Prchal-Murphy; David Partida; Manuel Eguren; Karoline Kollmann; Marta Gómez de Cedrón; Pierre Dubus; Marta Cañamero; Dolores Martínez; Veronika Sexl; Marcos Malumbres
Journal:  Blood       Date:  2014-08-25       Impact factor: 22.113

10.  Cell-cycle control of developmentally regulated transcription factors accounts for heterogeneity in human pluripotent cells.

Authors:  Amar M Singh; James Chappell; Robert Trost; Li Lin; Tao Wang; Jie Tang; Brittany K Matlock; Kevin P Weller; Hao Wu; Shaying Zhao; Peng Jin; Stephen Dalton
Journal:  Stem Cell Reports       Date:  2013-12-05       Impact factor: 7.765

View more
  65 in total

1.  Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.

Authors:  Kathleen Hanlon; Alex Thompson; Lorena Pantano; John N Hutchinson; Arshed Al-Obeidi; Shu Wang; Meghan Bliss-Moreau; Jennifer Helble; Gabriela Alexe; Kimberly Stegmaier; Daniel E Bauer; Ben A Croker
Journal:  Cancer Genet       Date:  2019-06-12

2.  The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer.

Authors:  Chi-Wen Luo; Ming-Feng Hou; Chia-Wei Huang; Chun-Chieh Wu; Fu Ou-Yang; Qiao-Lin Li; Cheng-Che Wu; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Circular RNA circ_ASAP2 promotes cell viability, migration, and invasion of gastric cancer cells by regulating the miR-770-5p/CDK6 axis.

Authors:  Bing Chen; Fei Ji; Xinian Wen; Zhong Jin
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

Review 4.  A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?: Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets.

Authors:  Patrick Y Lang; Timothy R Gershon
Journal:  Bioessays       Date:  2018-03-26       Impact factor: 4.345

5.  A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation.

Authors:  Eszter Doma; Isabella Maria Mayer; Tania Brandstoetter; Barbara Maurer; Reinhard Grausenburger; Ingeborg Menzl; Markus Zojer; Andrea Hoelbl-Kovacic; Leif Carlsson; Gerwin Heller; Karoline Kollmann; Veronika Sexl
Journal:  Blood Adv       Date:  2021-01-12

6.  Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6.

Authors:  Jian Cao; Yuan Zhang; Juan Mu; Dazhen Yang; Xiaoyan Gu; Jing Zhang
Journal:  Hum Cell       Date:  2021-04-03       Impact factor: 4.174

7.  Simulated microgravity reduces proliferation and reorganizes the cytoskeleton of human umbilical cord mesenchymal stem cells.

Authors:  H N Quynh Chi; H Nghia Son; D Chinh Chung; L D Huan; T Hong Diem; L T Long
Journal:  Physiol Res       Date:  2020-09-09       Impact factor: 1.881

8.  Notch signaling defects in NK cells in patients with cancer.

Authors:  Gulnur K Zakiryanova; Elena Kustova; Nataliya T Urazalieva; Emile T Baimukhametov; Valeriy A Makarov; Gulmariya M Turaly; Galina V Shurin; Zarema M Biyasheva; Narymzhan N Nakisbekov; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

9.  CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Authors:  Florian Bellutti; Anca-Sarmiza Tigan; Sofie Nebenfuehr; Marlies Dolezal; Markus Zojer; Reinhard Grausenburger; Svenja Hartenberger; Sebastian Kollmann; Eszter Doma; Michaela Prchal-Murphy; Iris Z Uras; Alexander Höllein; Donna S Neuberg; Benjamin L Ebert; Anna Ringler; Andre C Mueller; Joanna I Loizou; Philip W Hinds; Claus Vogl; Gerwin Heller; Stefan Kubicek; Johannes Zuber; Marcos Malumbres; Matthias Farlik; Andreas Villunger; Karoline Kollmann; Veronika Sexl
Journal:  Cancer Discov       Date:  2018-06-13       Impact factor: 39.397

10.  CDK6 Is a Therapeutic Target in Myelofibrosis.

Authors:  Avik Dutta; Dipmoy Nath; Yue Yang; Bao T Le; Golam Mohi
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.